Class IIITerminatedD-0248-2019
Drug recall · November 21, 2018
ERBITUX CETUXIMAB Injection recall
Why: Labeling: Missing label; potential for missing primary container label on the vial.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
ERBITUX CETUXIMAB Injection, 200 mg/100 mL (2 mg/mL), 100 mL per single-use vial, Rx only, Manufactured by: ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, Branchburg, NJ 08876 USA. NDC: 66733-958-23
- Lots / codes
Lot number: C1700167, exp 9/2020
- Quantity
- 9,380 vials
- Company
- Eli Lilly & Co, Indianapolis, IN
- Distribution
- AL, AZ, CA, KS, LA, MS, OH, OR, TN, TX and Puerto Rico
- Initiated
- November 8, 2018 · Voluntary: Firm initiated
- Classified
- November 15, 2018
- Reported
- November 21, 2018
- Ended
- April 22, 2020
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.